Hepatitis C virus NS3/4a protease inhibitors
- 23 August 2016
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Pharmacology
- Vol. 30, 84-92
- https://doi.org/10.1016/j.coph.2016.07.015
Abstract
Hepatitis C virus (HCV) infection is a major health issue around the world and HCV NS3/4a protease inhibitors have been the focus of intensive research for the past 20 years. From the first identification of substrate-derived peptide inhibitors to the complex, macrocyclic compounds, including paritaprevir and grazoprevir, that are currently available, the field has used structure-based design to confront the issues of potency, resistance and pharmacokinetics. Numerous breakthrough structures from a multitude of companies have led to compounds that are now key components of combination therapies with cure rates of >90%. Herein, we detail the compounds that have advanced to clinical trials including their design and their impact on the NS3/4a protease field.Keywords
This publication has 51 references indexed in Scilit:
- Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?PLOS ONE, 2015
- Expert opinion on the treatment of patients with chronic hepatitis CJournal of Viral Hepatitis, 2009
- The global burden of hepatitis CLiver International, 2009
- Unravelling hepatitis C virus replication from genome to functionNature, 2005
- Genetic diversity and evolution of hepatitis C virus – 15 years onJournal of General Virology, 2004
- Fibrosis and disease progression in hepatitis CHepatology, 2002
- Peptide-based inhibitors of the hepatitis C virus serine proteaseBioorganic & Medicinal Chemistry Letters, 1998
- Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage ProductsBiochemistry, 1998
- Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor PeptideCell, 1996
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989